Marvel Biosciences reported that its drug candidate MB-204 significantly improved autism-related behaviors in a Shank3 mouse model, a genetic model linked to Phelan-McDermid syndrome. MB-204 outperformed Istradefylline, an approved Parkinson's drug, across most behavioral tests, suggesting its potential as a broad treatment for autism spectrum disorders. This adds to prior positive results in other neurodevelopmental disorder models, supporting MB-204's promise as a pan-spectrum autism therapy. The company plans further analysis and upcoming presentations to the scientific community.
Marvel Biosciences' MB-204 drug candidate is highlighted in this report, with Pluang's health sector showing 28 of 100 US stocks rising and 65 falling as of Oct 08, 2026 17:11 WIB. Among notable movers, NUWE traded at USD 0.66 with a 5.17% decline and a near-even Pluang order activity split of 52% Sell to 48% Buy, MESO was priced at USD 13.48 down 3.30%, and SANA rose 2.94% to USD 2.80 with 73% of orders buying. Typical hold times ranged from 14 to 26 days across these stocks.
Visa Canada's data reveals that the Toronto International Film Festival (TIFF) 2026 increased visitor spending by 12% compared to 2025, with international visitors spending about 40% more than Canadian cardholders. The festival attracted visitors mai...
Aclarion, Inc. has updated the enrollment criteria for its CLARITY clinical trial to better reflect real-world chronic low back pain patients and accelerate patient recruitment. The revised criteria, approved at most active sites, expand the pool of ...
Zscaler CEO Jay Chaudhry has sold 2,852 shares of the company, generating $550,000 from the transaction. This sale could indicate personal financial planning or portfolio rebalancing by the CEO. Investors might watch for any further insider activity ...
Ascentis Independent Advisors has expanded by adding four advisory teams from Raymond James Financial Services, bringing over $1 billion in client assets. These teams, based in California and Colorado, chose Ascentis to access enhanced planning, inve...
Nucor Corporation is investing $105 million to expand its Nucor Towers & Structures facility in Crawfordsville, Indiana, aiming to increase production capacity for utility poles and related products. This expansion will create 100 new jobs with avera...
